MedTrace Logo

IGF Level in Breast Cancer Patients Treated With Metformin

NCT05840068 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2023-05-03

No results posted yet for this study

Summary

The purpose of this study is to examine the impact of metformin as an adjuvant to chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast cancer in female patients.

Conditions

  • Breast Cancer Female

Interventions

DRUG

MetFORMIN 500 Mg Oral Tablet

MetFORMIN 500 Mg Oral Tablet

DRUG

Chemotherapy

The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05840068 on ClinicalTrials.gov